Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival

Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells

(2019) Jesus Luna et al.   Cancers

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

(2019) Timothy F. Cloughesy et al.   NATURE MEDICINE

Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

(2019) Kurt A. Schalper et al.   NATURE MEDICINE

Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors–Human Leukocyte Antigen Ligand Mismatch and Activation Receptor–Ligand Interactions

(2018) Heleen Neeltje Haspels et al.   Frontiers in Immunology

Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5

(2018) Mattias Carlsten et al.   OncoImmunology

Dual role of autophagy in hallmarks of cancer

(2017) Shikha Satendra Singh et al.   ONCOGENE

Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner

(2017) Silvia Würstle et al.   Oncology Letters

Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients

(2017) M. Bahador et al.   OncoImmunology

Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy

(2016) J. Y. Yoo et al.   CLINICAL CANCER RESEARCH

Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity

(2016) C. M. Suryadevara et al.   CLINICAL CANCER RESEARCH

A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas

(2016) Jeffrey J. Raizer et al.   JOURNAL OF NEURO-ONCOLOGY

Processing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells

(2015) Hans Jiro Becker et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Activation-Specific Metabolic Requirements for NK Cell IFN-γ Production

(2015) Molly P. Keppel et al.   JOURNAL OF IMMUNOLOGY

Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors

(2015) Andrea Gras Navarro et al.   Frontiers in Immunology

NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival

(2014) Andrea Gras Navarro et al.   JOURNAL OF IMMUNOLOGY

Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation

(2014) C Kao et al.   Cell Death & Disease

Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level

(2013) Justyna Kmiecik et al.   JOURNAL OF NEUROIMMUNOLOGY

Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

(2013) X Sui et al.   Cell Death & Disease

Nonclassical Antigen-Processing Pathways Are Required for MHC Class II-Restricted Direct Tumor Recognition by NY-ESO-1-Specific CD4+ T Cells

(2013) J. Matsuzaki et al.   Cancer Immunology Research

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules

(2012) P. Parham et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma

(2011) Agnete Svendsen et al.   ACTA NEUROPATHOLOGICA

Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis

(2011) T. Unterkircher et al.   CLINICAL CANCER RESEARCH

The dual role of autophagy in cancer

(2011) Eeva-Liisa Eskelinen   CURRENT OPINION IN PHARMACOLOGY

Induction of autophagy in temozolomide treated malignant gliomas

(2011) Manabu Natsumeda et al.   NEUROPATHOLOGY

Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia

(2010) S. Cooley et al.   BLOOD

Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics

(2010) Camilla Krakstad et al.   Molecular Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma

(2008) S. Armeanu et al.   CLINICAL CANCER RESEARCH